1. Scrip
  2. >>Business
  3. >>Strategy

NeRRe: Advancing Neurokinin Receptor Antagonists

 
• By Mike Ward

Starting the year with a cash injection of £23m, 2012 GSK spin-out NeRRe Therapeutics intends to advance its neurokinin receptor antagonist pipeline towards late-stage clinical development. CEO Mary Kerr spoke to Scrip's Mike Ward at the 2017 Biotech Showcase in San Francisco.

NeRRe Therapeutics Ltd., which was spun out of GlaxoSmithKline PLC in 2012, is advancing a pipeline of neurokinin receptor antagonists through the clinic, and earlier this year raised £23m. CEO Dr Mary Kerr explains how the company plans to generate Phase II data on orvepitant, a chronic respiratory candidate; and to advance NT-814 as a potential non-hormonal treatment of distressing post-menopausal vasomotor symptoms.

NeRRe's products originated in GSK and were taken over when the UK big pharma decided to deprioritize neurosciences and spin...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.